For Japanese patients with CML, hyperbilirubinemia may be predicted before nilotinib treatment and controlled by reducing the daily dose of nilotinib in patients with UGT1A9 polymorphisms. The gene discussed is UGT1A9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.